A5006341868- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Lung Cancer Treatments and Mutations
- Pulmonary Hypertension Research and Treatments
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Sarcoidosis and Beryllium Toxicity Research
- Lung Cancer Diagnosis and Treatment
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Eosinophilic Disorders and Syndromes
- Pleural and Pulmonary Diseases
- Chronic Myeloid Leukemia Treatments
- PI3K/AKT/mTOR signaling in cancer
- Colorectal Cancer Treatments and Studies
- Cancer Diagnosis and Treatment
- Extracellular vesicles in disease
- Gastric Cancer Management and Outcomes
- Medical Imaging and Pathology Studies
- RNA modifications and cancer
- Oral and gingival health research
- Colorectal and Anal Carcinomas
- Gestational Trophoblastic Disease Studies
- Cryospheric studies and observations
- Ultrasound and Hyperthermia Applications
- Drug-Induced Adverse Reactions
- Antifungal resistance and susceptibility
Nippon Medical School
2016-2025
Weatherford College
2022
Kubota (Japan)
2022
Koto Hospital
2021
Juntendo University
2021
Pulmonary Associates
2021
Pembrolizumab is an immune checkpoint inhibitor (ICI) of programmed cell death-1 category, used for treating various types cancer. ICIs can sometimes result in immune-related adverse events. Allergic bronchopulmonary mycosis (ABPM) induced by ICI has rarely been reported. We hereby report the case 83-year-old woman who experienced non-Aspergillus ABPM with eosinophilia pembrolizumab that had prescribed bladder Steroid monotherapy prednisone was successful and could be resumed. Through...
Although aberrant proliferation and activation of lung fibroblasts are implicated in the initiation progression idiopathic pulmonary fibrosis (IPF), underlying mechanisms not well characterized. Numerous microRNAs (miRNAs) have been this process; however, miRNAs derived from exosomes relevance such to fibroblast-to-myofibroblast differentiation understood. In study, we attempted identify exosome-derived relevant development.Using miRNA array analysis, profiled expression sera C57BL/6 mice...
Idiopathic pulmonary fibrosis (IPF) is a progressive disease with high mortality, and the pathogenesis of still incompletely understood. Although lymphocytes, especially CD4+CD25+FoxP3+ regulatory T cells (Tregs), have been implicated in development IPF, contradictory results reported regarding contribution Tregs to both animals humans. The aim this study was investigate whether specific cell subset has therapeutic potential inhibiting bleomycin (BLM)-induced murine fibrosis. C57BL/6 mice...
While high-level evidence is lacking, numerous retrospective studies have depicted the value of supplemental oxygen in idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases, its use should be encouraged where necessary. The clinical course survival patients with IPF who been introduced to therapy still not fully understood. objective this study was clarify overall survival, factors associated prognosis, causes death after start therapy. This a prospective cohort...
Thyroid transcription factor-1 (TTF-1) is expressed in approximately 70% of lung adenocarcinomas and one the most reliable makers to distinguish primary adenocarcinoma from metastatic disease. TTF-1-negative status a poor prognostic factor, associated with efficacy immune checkpoint inhibitor (ICI) monotherapy. However, relationship between TTF-1 expression ICI plus chemotherapy still unclear.We performed retrospective analysis 129 consecutive patients advanced non-squamous non-small cell...
Long-term maintenance steroid therapy (MST) is often necessary for repeated relapses of chronic eosinophilic pneumonia (CEP). Because relapse does not indicate a worse prognosis, determining the optimal dose to avoid overtreatment presents clinical challenge. Our primary objective was evaluate MST prevent relapses, and secondary objectives included identifying serum eosinophil count at background factors relapse. A multicentre retrospective study conducted on patients with steroid-treated...
Background: Idiopathic pleuroparenchymal fibroelastosis (IPPFE) was recently proposed as an entity to be included among rare idiopathic interstitial pneumonias (IIPs). However, the cause, clinical features and prognosis of this have not been elucidated. Objectives: We aimed examine features, outcomes prognostic factors for IPPFE in comparison those pulmonary fibrosis (IPF). Methods: retrospectively analyzed 20 patients with 71 IPF. compared blood examination data, respiratory functions at...
Objectives Acute exacerbation of idiopathic pulmonary fibrosis (IPF-AE) has been recognized as a fatal disorder, but the exact prognostic factors are unknown. The aim present study was to analyze clinical characteristics patients with IPF-AE and identify factors. Methods medical records 59 cases were retrospectively reviewed. Clinical data, laboratory radiographic findings, treatment, time from onset symptoms initiation corticosteroid pulse therapy, i.e. symptom duration, outcome analyzed....
Background: Primary pulmonary choriocarcinoma (PPC) is a rare malignancy, and only 41 PPC cases have been reported in males up to 2021. Due its rarity, no standardized treatments for established. Cytotoxic chemotherapy has limited efficacy, the prognosis of advanced notably poor. Immune checkpoint inhibitors (ICIs) are expected provide long-term survival patients, but few reported. The optimal treatment not determined.
Sarcoidosis is a systemic granulomatous disease; however, the incidence of bone sarcoidosis relatively rare. The short tubular bones hands and feet are most frequently affected, while vertebrae pelvic rarely involved. We hereby report rare case multiple involving bones, evaluated before after steroid therapy using two different imaging modalities: scintigraphy A 18F-fluorodeoxyglucose positron emission tomography combined with computed (FDG-PET/CT). FDG-PET/CT effective for detecting...
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is the standard treatment for patients with non-small cell lung cancer harboring EGFR mutations. Although frequency of osimertinib-induced interstitial disease (osi-ILD) high, optimal after osi-ILD has not been established. This time, we focused on safety and efficacy gefitinib following osi-ILD.
Amrubicin, which is used as a chemotherapeutic agent for lung cancer, can induce interstitial disease. There insufficient evidence on the incidence of amrubicin-associated disease under practical use settings. We therefore investigated occurrence in patients with cancer who received amrubicin our institution. reviewed data all at Nippon Medical School Hospital from March 2002 to April 2015. Interstitial was diagnosed based clinical symptoms, radiographic findings and exclusion other...
Acute exacerbation of pre-existing interstitial lung disease (ILD) associated with systemic anticancer therapy is recognized as a life-threatening adverse event cancer treatment.Programmed cell death 1 (PD-1) checkpoint inhibitors, such nivolumab, often induce pneumonitis in patients cancer; however, the tolerance and safety nivolumab for advanced ILD are unclear.We report 72-year-old patient pathologically proven idiopathic pulmonary fibrosis who was treated nivolumab.She demonstrated an...
We report a case of pneumonitis with alveolar hemorrhage induced by herbal medicines in 73-year-old woman who was admitted to our hospital because dyspnea and an abnormal shadow on chest radiograph. She had received treatment numerous drugs, including the Seisin-renshi-in, Chotosan, Rikkunshi-to, Shakuyakukannzo-to. Chest radiography revealed diffuse ground-glass shadows both lungs, bronchoalveolar lavage fluid progressively hemorrhagic. A culture showed no evidence microorganisms. Moreover,...
Rationale: Black pleural effusion is a rare medical condition and diagnostic marker. Pancreaticopleural fistula one of the causes black effusion. Thus far, effusions caused by pancreaticopleural fistulae have mostly been reported in patients with alcohol-induced chronic pancreatitis. In this report, we present case associated autoimmune Patient concerns diagnosis: A 59-year-old female without history alcohol drinking presented to our hospital chief complaint dyspnea, as well chest back...
Abstract Background Rechallenge with platinum‐combination chemotherapy in patients advanced non‐small cell lung cancer (NSCLC) after disease progression on occasionally leads to a favorable response. The efficacy and safety of or without immune‐checkpoint inhibitor (ICI) for recurrent NSCLC surgery followed by adjuvant platinum‐doublet remains uncertain. Methods Patients who relapsed plus received ICI between April 2011 March 2021 at four Nippon Medical School hospitals were retrospectively...
Eosinophilic bronchiolitis is a disease concept reported in Japan 2001, that presents with accompanied by eosinophilia the blood and lungs. In 2013, hypereosinophilic obliterative bronchiolitis, as group of presenting eosinophilic was proposed France. The relationship between other eosinophil-related diseases has not been clarified. Herein, we report case 56-year-old female patient without asthma, which developed into pneumonia. Treatment oral prednisone improved respiratory function....
In pulmonary hypertension (PH) associated with chronic lung disease (CLD), identifying patients who would benefit from vasodilators is a significant clinical challenge because the presence of PH poorer survival. This study evaluated severity circulation impairment in CLD-PH using perfusion single-photon emission computed tomography/computed tomography (SPECT/CT). single-center, observational enrolled had mean arterial pressure (PAP) ≥ 25 mmHg, as confirmed by right heart catheterization. The...
Malignant pleural effusion (MPE) remains a negative prognostic factor in non-small cell lung cancer (NSCLC), even after the emergence of immune checkpoint inhibitors. Vascular endothelial growth (VEGF) plays pivotal role pathogenesis MPE. Bevacizumab, humanized monoclonal antibody against VEGF, is key agent for patients who develop However, it unclear whether MPE poor with advanced non-squamous NSCLC receiving treatment atezolizumab plus bevacizumab, carboplatin, and paclitaxel (ABCP)...
背景.免疫チェックポイント阻害薬による劇症1型糖尿病は稀な有害事象である.肺癌においては非小細胞肺癌での報告が散見される.今回,小細胞肺癌に対するデュルバルマブ投与後に劇症1型糖尿病を発症した症例を経験した.症例.71歳男性,Performance Status 1.糖尿病の既往歴なし.進展型小細胞肺癌cT4N3M1b stage IVAに対して,20XX年5月よりカルボプラチン+エトポシド+デュルバルマブ併用療法が開始された.Day 27より食欲不振,倦怠感が出現し,2コース目投与日(day 30)の検査で高血糖(761 mg/dl),尿ケトン陽性,尿中Cペプチド3.9 μg/日を認め,デュルバルマブによる劇症1型糖尿病と診断した.インスリン治療で血糖コントロールが得られた後に,カルボプラチン+エトポシド併用療法が3コース行われた.著明な治療効果が得られ,その後病状進行はみられていない.結論.小細胞肺癌に対するデュルバルマブ投与後の劇症1型糖尿病発症は稀であるが,緊急性のある免疫関連有害事象であり注意を要する.